NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NON-ALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NON-ALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New shot aims to shrink fatty liver and shed pounds
Disease control CompletedThis study tested if a weekly injection called survodutide, combined with diet and exercise counseling, could help people with a fatty liver disease called NASH and obesity. Over 200 adults received either the real medicine or a placebo (dummy shot) for about a year. Researchers …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug shows promise in reversing dangerous liver scarring
Disease control CompletedThis study tested whether a weekly injection called pemvidutide could help people with a serious fatty liver disease called NASH. Researchers compared the drug to a placebo in 212 adults to see if it could reduce liver inflammation and scarring. The main goal was to see if the dr…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill tested to fight dangerous fatty liver disease
Disease control CompletedThis study tested whether a new oral drug called HSK31679 could improve liver health in people with NASH, a serious form of fatty liver disease that causes scarring. About 186 Chinese adults with confirmed NASH and moderate liver scarring took either the drug or a placebo pill da…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Early trial tests new Drug's effect on damaged livers
Disease control CompletedThis small, completed study tested whether a one-month course of an experimental drug called TRO19622 was safe and could improve liver health in people with NASH, a type of fatty liver disease. Twenty-two adults with confirmed NASH received either the drug or a placebo. The main …
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
First human test for liver disease drug begins
Knowledge-focused CompletedThis was the first study in people for a potential new drug called AZD4076, which is being developed for a serious liver disease called NASH. The main goal was to check if single, increasing doses of the drug were safe and well-tolerated in 40 healthy male volunteers. Researchers…
Matched conditions: NON-ALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 04, 2026 05:21 UTC